Time magazine has named internationally renowned breast cancer oncologist Laura Esserman, MD, MBA, to the 2016 TIME 100, the magazine’s annual list of the 100 most influential people in the world.
Esserman has been at the forefront of efforts to change the delivery of breast cancer services as well as information systems used to support both research and patient care.
Esserman is now a professor of Surgery and Radiology at UCSF and a faculty member of the UCSF Helen Diller Family Comprehensive Cancer Center. She is also a practicing surgeon and breast cancer oncology specialist at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of director since 1996.
Innovative Approaches to Battling Breast Cancer
At UCSF, Esserman has worked in the clinic, in research, and with interdisciplinary teams of clinicians and researchers. The result of her work has been a cross-disciplinary approach to battling breast cancer, including the best care for patients and the best platform to integrate translational research into breast cancer care.
Esserman is a leader of the innovative I-SPY TRIAL model, designed to accelerate the identification and approval of effective new agents for women with high risk breast cancers. The goal of the I-SPY TRIAL model is to shave several years and tens to hundreds of millions of dollars off the drug development process. The trial paradigm is now being developed for use in other disease domains.
In 2009, Esserman led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research as it follows 150,000 women from screening through treatment and outcomes.
In March 2015, she received one of the first five major grants funded through the Patient-Centered Outcomes Research Institute’s (PCORI) Pragmatic Clinical Trials initiative. The $14 million grant funds the WISDOM study to learn how to improve breast cancer screening by testing and comparing the safety and efficacy of a personalized screening strategy informed by each woman’s breast cancer risk and preferences against the standard of annual screening. The WISDOM Study is slated to open in late summer 2016.
Internationally Recognized Thought Leader
The findings from her research have been published in 250 articles in peer-reviewed journals covering all aspects of breast health on topics that include information systems, immunology, decision-making, health policy and the use of imaging.
Esserman is nationally and internationally known as a thought leader on the topics of over-diagnosis and over-treatment, calling attention to, as well as developing solutions to address, these problems. Her innovative research and passion as a patient advocate has been recognized countless times throughout her career. Most notably and recently, Esserman was awarded the Luminary Award at the Personalized Medicine World Conference in January 2016 and the Stanford Graduate School of Management’s prestigious Ernest C. Arbuckle Award in March 2016.
The TIME 100 list, now in its 13th year, recognizes the activism, innovation and achievement of the world’s most influential individuals.
The full list and related tributes appear in the May 2 issue of Time, available on newsstands on April 22, and now at time.com/time100.
This article was originally written by Mike Billings and published by UCSF.